Supplementary Financial Information (Tables)

3 Months Ended

Mar. 31, 2024

Supplemental Financial Information [Abstract]

Schedule of Restricted Cash

Cash, cash equivalents and restricted cash amounts are as follows:

	March 31, 2024		December 31, 2023
Cash and cash equivalents	$	685	$	519
Restricted cash
Litigation deposits in Brazil	26		27
Escrow and cash collections related to secured borrowing arrangements and receivable sales(1)	39		49
Other restricted cash	22		22
Total Restricted cash	87		98
Cash, cash equivalents and restricted cash(2)	$	772	$	617

_____________

(1)Includes collections on finance receivables pledged for secured borrowings or sold that will be remitted to lenders in the following month.

(2)Xerox Corporation Cash, cash equivalents and restricted cash of $769 excludes $3 of cash held by Myriad Ventures Fund I LP.

Schedule of Restricted Cash Balance Sheet Location

Restricted cash is reported in the Condensed Consolidated Balance Sheets as follows:

	March 31, 2024		December 31, 2023
Other current assets	$	60	$	70
Other long-term assets	27		28
Total Restricted cash	$	87	$	98

Schedule Cash Flow Information

Summarized cash flow information is as follows:

	Location in Statement of Cash Flows	Three Months Ended March 31,
Source/(Use)		2024		2023
Provision for receivables	Operating	$	14	$	(5)
Provision for inventory	Operating	43		5
Depreciation of buildings and equipment	Operating	14		16
Depreciation and obsolescence of equipment on operating leases	Operating	28		27
Amortization of internal use software	Operating	7		10
Amortization of acquired intangible assets	Operating	10		11
Amortization of patents(1)	Operating	2		2
Amortization of customer contract costs(2)	Operating	16		16
Cost of additions to land, buildings and equipment	Investing	(8)		(6)
Cost of additions to internal use software	Investing	(2)		(2)
Payments to acquire noncontrolling interests - Xerox Holdings	Investing	(11)		(3)
Common stock dividends - Xerox Holdings	Financing	(33)		(41)
Preferred stock dividends - Xerox Holdings	Financing	(4)		(4)
Payments to noncontrolling interests	Financing	(1)		(1)
Repurchases related to stock-based compensation - Xerox Holdings	Financing	(9)		(6)

_____________

(1)Amortization of patents is reported in (Increase) decrease in other current and long-term assets in the Condensed Consolidated Statements of Cash Flows.

(2)Amortization of customer contract costs is reported in (Increase) decrease in other current and long-term assets in the Condensed Consolidated Statements of Cash Flows. Refer to Note 3 - Revenue - Contract Costs for additional information.